New Delhi: Zydus Lifesciences Ltd announced on Wednesday that its cancer treatment drug, Mamitra, has received marketing approval from Mexico's regulatory authority, COFEPRIS (Federal Commission for the Protection Against Sanitary Risk).

Mamitra, a biosimilar of Trastuzumab, is designed to treat breast cancer and advanced gastric cancer. With the new approval, Mamitra will be available in two strengths: 150 mg and 440 mg. This move is significant as breast cancer has surpassed prostate and colorectal cancers to become the most commonly diagnosed cancer in Mexico.

Dr. Sharvil Patel, Managing Director of Zydus, expressed enthusiasm about the approval. "The launch of Mamitra in Mexico marks a significant expansion of our biosimilar portfolio, allowing us to offer affordable, life-saving treatments to new markets, especially in oncology," he stated.

The Trastuzumab biosimilar was developed by Zydus's in-house research team at the Zydus Research Centre (ZRC) and was first introduced in India in 2016 under the brand name Vivitra. Since its launch, it has been used to treat approximately 100,000 patients.

Latest Health Updates:

Peru Moves Forward in Expanding Cancer Care Nationwide

Cancer Cases on the Rise: 5 Most Common Types of Cancer in Men

Cancer Cases in India on the Rise: Government Data Reveals Alarming Increase